Brokers note28 Jun 2023 14:49
This PART of brokers notes I like
This weakness looks overdone, pricing in significant downgrades that, we believe, will not materialise," they said in a research note sent to clients.
"JD is too cheap for the quality and double-digit compounding growth on offer, with a huge global growth opportunity not fairly reflected in valuation."
Their recommendation stayed at 'buy' and their target price was unchanged at 210.0p.